_400mg_logo-header.png){kind=logo}
Tyronib® (Imatinb Mesylate) 400mg ⇒ Generic
Taj Pharma is one of the largest generic pharmaceutical company in India.We hold top positions in different established markets worldwide and are building a strong presence in many emerging generics markets.
Today, we market more than 500 barded and 4600 generics compositions to consumers in more than 40 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products.
At Taj Pharma, we are always ready to meet the challenges of the dynamic global pharmaceutical industry with its numerous and wide-ranging issues – from complex research, development and regulatory conditions to rapidly changing consumer demands.
Our Generics portfolio offers over 1500 products in the major therapeutic areas of gastro-intestinal, cardiovascular, pain management, oncology, anti-infectives, paediatrics and dermatology. Brands like Alzocum®, Benacof, Wallbrurate®, Coversec, Cadrol, Humogen and Merokem enjoy leadership positions in several key markets, including India, Russia & other countries.
Our deep customer relationships, quality medicines and consistently delivered promise make us a trusted brand across the world.We have capitalized on every opportunity to bring our high-quality products to more people around the world. A synchronized supply chain that leverages our strong product development capabilities, state-of-the-art manufacturing and vertical integration with our own APIs has created a creditable track record of successful launches.
Our generics offerings deliver quality at cost-effective prices in the highly regulated markets of the United States, UK and other Asian countries.
Today, we market more than 500 products to consumers in more than 40 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products.
At Taj Pharma, we are always ready to meet the challenges of the dynamic global pharmaceutical industry with its numerous and wide-ranging issues – from complex research, development and regulatory conditions to rapidly changing consumer demands.
Our Generics portfolio offers over 100 products in the major therapeutic areas of gastro-intestinal, cardiovascular, pain management, oncology, anti-infectives, paediatrics and dermatology. Brands like Omez, Ciprolet, Nise, Enam, Ketorol, Exifine and Cetrine enjoy leadership positions in several key markets, including India, Russia & other countries.
Our deep customer relationships, quality medicines and consistently delivered promise make us a trusted brand across the world.
We have capitalized on every opportunity to bring our high-quality products to more people around the world. A synchronized supply chain that leverages our strong product development capabilities, state-of-the-art manufacturing and vertical integration with our own APIs has created a creditable track record of successful launches.
Our generics offerings deliver quality at cost-effective prices in the highly regulated markets of the United States, UK and other Asian countries.
Today, we market more than 500+ products to consumers in more than 40 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products.
For More information visit www.tajpharma.com
Uses
Tyronib® (Imatinb Mesylate), is a targeted therapy used to treat certain types of Leukaemia and soft tissue sarcoma, it may also be used to treat other types of cancers as part of research trial.
Tyronib® (Imatinib Mesylate) may be used to treat:
- Chronic myeloid leukaemia (CML)
- A type of acute lymphoblastic leukaemia (ALL) called Philadelphia chromosome positive (Ph+ ALL)
- Gastro-intestinal stromal tumours (GISTs)
- A rare type of soft tissue cancer called dermatofibrosarcoma protuberans (DFSP)
- Other types of cancers as part of a research trial.
Important Safety Information
-
Pregnancy Category D:Imatinib can cause fetal harm when administered to a pregnant woman. There have been post-market reports of spontaneous abortions and infant congenital anomalies from women who have taken Imatinib.
There are no adequate and well-controlled studies with Imatinib in pregnant women. Women should be advised not to become pregnant when taking Imatinib. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. - Nursing Mothers:Imatinib and its active metabolite are excreted into human milk. Based on data from three breastfeeding women taking Imatinib, the milk:plasma ratio is about 0.5 for imatinib and about 0.9 for the active metabolite.
- Pediatric Use:Imatinib safety and efficacy have been demonstrated in children with newly diagnosed Ph+ chronic phase CML and Ph+ ALL. There are no data in children under 1 year of age.
- Geriatric Use: In the CML clinical studies, approximately 20% of patients were older than 65 years. In the study of patients with newly diagnosed CML, 6% of patients were older than 65 years. No difference was observed in the safety profile in patients older than 65 years as compared to younger patients, with the exception of a higher frequency of edema. The efficacy of Imatinib was similar in older and younger patients.
